RAG-01

DRUG2 trials

Sponsors

Ractigen Therapeutics.

Conditions

Non-Muscle-Invasive Bladder Cancer (NMIBC)Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

RecruitingNCT06351904

Ractigen Therapeutics.Non-Muscle-Invasive Bladder Cancer (NMIBC)

Start: 2024-04-03End: 2028-08-31Target: 72Updated: 2025-09-11

Phase 2

A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).

Not yet recruitingNCT07777848

Ractigen Therapeutics.Non-muscle Invasive Bladder Cancer (NMIBC)

Start: 2026-09-01End: 2029-03-01Target: 114Updated: 2026-09-15

Related Papers

First-in-human study of RAG-01: A novel small activating RNA therapeutic in BCG failure non-muscle invasive bladder cancer (NMIBC) patients.

Journal of Clinical Oncology2025-05-28